Cargando…
CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with...
Autores principales: | Lopez, Santiago J., Williams, H. James, Hogan, Thomas Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504490/ https://www.ncbi.nlm.nih.gov/pubmed/37719181 http://dx.doi.org/10.1016/j.eucr.2023.102421 |
Ejemplares similares
-
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015) -
CHEK2
(∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014) -
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015) -
CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007) -
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004)